2018
DOI: 10.1016/bs.seda.2018.06.014
|View full text |Cite
|
Sign up to set email alerts
|

Drugs in Tuberculosis and Leprosy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 62 publications
0
1
0
Order By: Relevance
“…It is a component of the Terizidone formulation and works by inhibiting the formation of bacterial cell walls by specifically targeting enzymes that are essential for peptidoglycan synthesis, such as alanine racemase (AlrA) and D-alanine ligase. The medication prevents bacteria from manufacturing their cell walls by interfering with these mechanisms [108][109][110]. Additionally, cyclorine inhibits the activities of alanine permease and Dalanyl-D-alanine synthetase, weakening the bacterial cell wall and causing bacterial cell death [111].…”
Section: Ethambutolmentioning
confidence: 99%
“…It is a component of the Terizidone formulation and works by inhibiting the formation of bacterial cell walls by specifically targeting enzymes that are essential for peptidoglycan synthesis, such as alanine racemase (AlrA) and D-alanine ligase. The medication prevents bacteria from manufacturing their cell walls by interfering with these mechanisms [108][109][110]. Additionally, cyclorine inhibits the activities of alanine permease and Dalanyl-D-alanine synthetase, weakening the bacterial cell wall and causing bacterial cell death [111].…”
Section: Ethambutolmentioning
confidence: 99%
“…Despite the effectiveness of BDQ and delamanid, a startling rate of resistance shortly after its launch was observed, especially for BDQ [33,34,243]. Currently, cautious use of BDQ and delamanid is in play due to the possibility of cardiotoxicity [244,245].…”
Section: Drug Repurposingmentioning
confidence: 99%